OpGen Inc (NASDAQ:OPGN)’s share price hit a new 52-week high and low during trading on Wednesday . The stock traded as low as $1.62 and last traded at $1.70, with a volume of 30856 shares trading hands. The stock had previously closed at $1.63.
OPGN has been the topic of several analyst reports. Zacks Investment Research downgraded OpGen from a “buy” rating to a “hold” rating in a report on Wednesday, January 10th. ValuEngine upgraded OpGen from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. Finally, HC Wainwright set a $9.00 price target on OpGen and gave the company a “buy” rating in a report on Thursday.
The company has a current ratio of 1.23, a quick ratio of 1.13 and a debt-to-equity ratio of 0.03.
An institutional investor recently raised its position in OpGen stock. Vanguard Group Inc. lifted its stake in OpGen Inc (NASDAQ:OPGN) by 1.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 342,860 shares of the medical research company’s stock after acquiring an additional 5,500 shares during the period. Vanguard Group Inc. owned approximately 1.25% of OpGen worth $219,000 at the end of the most recent reporting period.
ILLEGAL ACTIVITY WARNING: “OpGen (OPGN) Reaches New 1-Year High and Low at $1.62” was originally published by Ticker Report and is owned by of Ticker Report. If you are accessing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The original version of this story can be read at https://www.tickerreport.com/banking-finance/3334846/opgen-opgn-reaches-new-1-year-high-and-low-at-1-62.html.
OpGen Company Profile
OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.